/
11697
: *
! "
#$ % &'! &
.
)*
:+& ! , % [email protected]
D miR-378
! "
#
$ % #
#
&
' (% )
* B
1
*2
1 - ! "
# $
# .&
2 - (
) *
# $ ! "
# .&
! / #
$%&
! / ' 4
/ )
$ 97
,$ $ / 78
: 25 / 7 / 97 :
12 / 9 / 97
:
! " B
#$%&
'
"
(
# $)
*
"
+ , -(
+
$ ,! ( !.$/,$
$ .
( # 1 2# 3 45 6
7 ) + , 86,
+D mir-378 ) " 9$ 4 : - !
45 6 . ! B ;
!$< "
: - ! ,! "
/
=> ?!$
# @ 7 ) + + D miR-378
"
"
A, 1$ , >( +
!
!
! ! "
B)- "
B
. " 7
C+! + $ :
45 6 7 ! 150
( + @ ? + " B)" + 1$ , >( + " , " ! ! " ! G %#
H ! I )
! ! H"
86, . # ! J 45 6 !$ " B)" K & + 1$ , >( + " , "
" $#LDNA C+!
MH # N - O A)H,
H . H"
PQR 7 4 7 ) +
C+! D -PCR
" +RFLP miR-378
M -PCR ( %),SSCP
.=
1$# HJ 1 H" ! H( H" "
# + ? 1 T - + ! -,
+
! ? K # U,$
. )? @ ! J G / + * !$ SPSS
)?
:
1 2# V )#
4 3 ?B)W G5 X $#L ! !
7 H) + H# $ MH ?!$ H/ H # ! D
rs1544410
$HR+
) #
119 / 0
= G5] + (P
" (! $ " 1 $ & " # $ C
$ )? @ <# ! _ 6W H 4 `B)HW ! " + =5 , ? 7 ".
!
"
# + ? M /5 M $#L + /
rs1076064 1L
miR-378
) $R+
0037 / 0
= .( P
* )# + c "
@ :
/ rs1544410 7 ) +
$H#L H# + ? $H # 1 " 1 $ . ! # _ ! >" P #D A/G
7 ) + 5 4? " de 7 ! G5] Q + ! #D
6W " (! $ " 1 $ & "C _
. $ )? @ <# ! # $
L + /(
:
=> ?!$ / 7 ) + B
D miR-378 .
6 . 7#
6 ) * ) 8 9. & : * B
; . )( 3 * 2 5 1 < ( # & 0 6 . 7# =
)B
(HBV
@ )
1 ( 6 . 7# .
5 ( 3 ( 5 9* A HBV
:B & 98 6 B38 C ( - D. 6 & 98 & 98 & ( )( 3 * 2 * * D*
:#
) 2 E 5 2 3F. .(
5 . 10 I(
$ :B 1 2 350
* ! 1 C &
: 0# * 2 K 6 . 7#
) 3 .(
LM * & ( 3 * 2
N B ( K M & " * 6 C O D P . 7# ) : ( E :5 * (
) 7-4 & .(
- KD. P E 6 2 3F. 98 65 9*
5 / 1
)( 3 * 2 & 98 ( C &
) 8 < .(
* ! & K U 5 * DL: ( & ( E HBV
( V ; (
- D.
3 ( E 6 B38 I(
HBV
: 0# 6-W )
9 5 C .(
12 ( ( ( * & I
D1 ) 3 O D :5 * = 2 YV ! 6 3# KZ $ & E E 2 * O D * ( HBV
) 9 * & 5 K * ( ( * ( O D [ 5 .6 = 2 & ! & * 6-W * \ ]F* " $
* ^ K1 )
9 ( .
&
* 6 C YM HBV
3$(
* Y* V A( I 8 .
( N B LM P * Y -.
& 5
YV * 2 K : 0#
. ( O $ _ $ * C 20E
6 . 7#
6 . 7# B
2 * 3 B
HBIG)
& . (
)( 0*
( O D [ . (HBV
( 9 E
(
$ E 6 C HBV
YM 3$(
:#
*
& K
P *
`(
# E * Y U a
A V
"
b c V 6 2 3#
( a K
&!
*
( a Y E 25 ( 6
) 10 (.
A B L -V * 8 .
* Y
;-.
* 6 C YM 3$(
* ) (
HBV
KE 3 5 )
11 (.
* 2 d
# : 2 3
6
^D 39 ( 6 C YM 3$(
HBV
) * :E .
* 2 O $ ( :e B L 6 0$
* 6 C YM 3$(
* ( *HBV
E
:#
A a /#
3E ( ( , -.(
2 * Y
Y 6 C YM 3$(
( HBV
=
6 ) 12 (.
6 . 7# & : 0E N B ( 1 ) *B
5 I . LM .
* 2 O $
^F*
e E
20E
# ! ) * ) # b ( f * 61 (
& K
(
& : 0E .
::E ) 13 ( . &
2 E 6 5 6 B1 2 0 . E & * * D
( " C5! * @: 2 0 . E ( O * ! ) g ( h 5 = 3
! & *K * &
5 ) 14 15 .(
2 . * &! -3E D
* ( E 6 . 7# & : 0E * )
, -.( ( B
6 ) 16 .(
miRNAs
( :3 / 0 O :E ( #
;-. ) # )( 3 * M * ( ( ^D & ( 0 * 5 8 & * ( O M * HBV
) 17 & .(
= 2 * ! ( O a ( E 6 5
miR-378
& * ^# E * ) 5 8
18 & K (
2 j ] O a ( E 6 5
D miR-378
* ^ K1
6 2 2 j #
) 19 .(
, -.( ( * B L 2 j # /0 1(
2
D miR-378
*
* F
& : 0E (
) #(
( ( * - 7# * 6 .
B
2 K . 5 *
C+! + $
B L B L _ $ ) ) ( )
-
* ) # 5
E ) * 2 B.
B.
k : 3 698 2 ( *
( K1 l- 4 /@$
PS 3 * * ( E
& * k _
e r ( z
O 1
. - 4 N=Z2R/E2
* I 1
, -.( ( * /0 1(
2 D miR-378
) 34 5 ) 3$
/
11897
& : 3a 95 I(
C . 5 mL )( :B (
9 ! 05 / 0 I(
( 5 1 <
. ) 3 ) (
& M 150 C : ( ( * ) #(
32 . 33 Y 5
1 6 . 7# * * & : 0E D* * ) 1 & : 0E D* * ( ( * ) #( O :E
.6 5 B L 6 . 7# * * (
( * 2
4 ( a * B L ( ( 3 * O :E 1 : )
$ 2 "
32 . 33 . * O & ( 3 * # 3
< 64. K -. 3 2 * & ( 3 * * ::E B8 ) # O a ( n B 5K 94
. 96 .6 5 9.
) * U -5 3 o ( & M 3 9. B*
p F
) 5 C DNA 20
.(
p F [ PDNA
6 6 3E 6 C E . 2 B. 5 p F DNA
) * DNA 6-3E
1 7 "
6 C E
( ! O ) ( * ( 1 o ( DNA 5 C
.
( ! O ) ( * ( 1 o ( ( 2µl
DNA 1
( * E ( 3 * : q. o
) K Fermentas ( 0 1
p F ( ! O ) ( * 5
/ 1 ( 1 I(
5
DNA ( D 6: ( 1 A 5 0 D c a 3 #
) # * * 3 - 4 ( DNA
[7 . 5
@ 698 k : ) # g!
) BLV W . PCR
; . <
( K1 oligo7
$ a . 5 C
C ( ) K8 6< g k : ) # g! 60 ) O 8 ( ; 5 1
) ( 2 .6 5 ( ! (
I+ R 1 . 45 6 7 ! )? @! ( " @ f] 3 gA2
K #
(′5-->′3) 5 $
VitD.F GGGCAACCTGAAGGGAGACG
VitD.R GCCCCTCTTTGGACCTCATCA
miR-378.F TCCTATCAATTACATTTCCCAAGTTG miR-378.R TGAAAGTTAATCTGGGACATTTGCT
I+ R
2 .
U 3 gA2
,! " "PCR
45 6 !$ /
M e )
( ( b D V ) &
1 65
) 95
5 D V
35 65 M e ) ) 95 30
b
].
# g! O 60
30 b
;0*
72 30
b
^:E @ B*
PCR ) # ) ( * YI $ AP ]4
( ! O 5 / 1 I(
5 ( 1 [7
* .
Merck)
& 3 ! ( )K ! r ( ) * # 698 DNA
C O ) ( ^C:* s( ( * * ( A BLV ( 5
; . 6 9 .61 @ )( -0 ( 2 *(
[
AP ]4 E( E & : 3a AP ]4 PCR
:e Y4
rs1544410 5
/ K ! C * o * ( BsmI
( V ( < ( A BLV C * ^98 1 1
.61 ( V K ! ( 5 . ) # 5( C. ( <: *
4 [ AP ] ) ( ( 1 ) 65 PCR
! Y E! O Merck)
& 3 ! ( . 5 C A t.
o ( * B L ( ) 9 5 :e ) * -RFLP
PCR ( * ( 61 ( V
. ( ^98 # A( I (
# 3 ( V ( * ( ( * < ( 3 #
5 A -b BLV ( a * ^98 8 . 61 .
C+!
G / + *
& V & * ( E * * # " ! ) #( E 3. [ ( < ( 1 & K u -: ) ( # 5 #
; 4 ( - 4 . 5SPSS
2 " 0 D ) *
Y B.
^98 ) # ( B 8 ( 1
o ( B L
[ ( K ! ( CI N 1 . 5 C [ ( K ! t v L 3. ( 0* t 2 " & * * * .6 YD 0
)?
( ( * , -.(
/0 1(
D2
miR-378 *
RFLP o ( PCR -
1 ) #
*
6 : ! 1 h . 5 :e 7 .
rs1544410 &
( A " # 1 VitD 100
C
* * ( 3 * 3
/ 1 ( I(
100 ( 3 * C
* * O :E 4
( A " 3# 1 5 - I(
* * O :E ( 3 * 3
/ 1 :B j M E 5 - I(
( A t. . ( 8 )(
m YI $ 1
! A B L ( ! 6 * )( ! . 5 ( * 7 . O 8 ( ! 6 * ) #
( 35 4 1 h . .6 5 wF r: 7 .
Y O ) # & 6 .
$ ( VitD
rs1544410 1(
( # 5 ( 3 *
O 8 5 &
E 6 5 1 ( GG
( 3 * ) 65 ( 1 2 * 40
/ 97 ( ( I(
) # 5 70 / 90 ( :B j M 2 E 5 # ( 5 * 3
) 1327 / p=0 .( ) # x . ( AG
AA
( 8 )( :B j M O 8)
5 .(
( * 1
5 :e 7 . rs1076064
&
miR-
A " # 1 378 ( 3 * (
60 / 10 ( I(
O :E 4 ( A " 3# 1 ( I(
( 3 * 30 / 9 E 5 - CI O :E ( I(
( 8 )( :B j M O 8)
6 .(
h .
r: 7 . Y
) # . O
& 6 miR-378 (
1( $ rs1076064
TT x .
(
) ( ( ( D 2 * O :E 96
( 3 * ( ( I(
86 ( 8 )( :B j M E 5 * I(
) # x . ( TT , TC
8 )( :B j M
O 8) ( 7
(.
I+ R 3 .
$#L # + ? h!
/ rs1544410 L " :$"
VitD 1 I , + ! " + @ !
case (n=100) control (n=100)
polymorp hism
Normal
%
Heterozygote
%
Homozygote
%
Normal
%
Heterozygote
%
Homozygote
% p value
VitD (rs154441
0)
٤ /
٩٧ ١ /٣ ١/٣ ٩٠/٧ ٤ ١/٣ ٠/١١٩
I+ R 4 . G5 X $#L ' $ 1L # $ + I #
VitD / # ! M ?!$
rs1544410
=5 , + ! " + @ + !
Case group (n=100)
Control group (n= 100) vitD
(rs1544410 ) % % Pvaluea OR 95 % CI
GG 97/40 90/70 0/1327 0/697 0/1-106/039
AG 1/30 4 0/3128 0/543 0/0-653/967
AA 1/30 1/30 0/2311 0/397 0/0-653/975
I+ R 5 .
/ $#L # + ? h!
rs1076064 1L " :$"
miR-378
=5 , + ! " + @ !
case (n=100) control (n=100)
polymor phism
Normal
%
Heterozygot e
%
Homozygote
%
Normal
%
Heterozygote
%
Homozygot e
%
p value mir378
(rs10760 64)
10 /
80 10/60 9/30 96/0 4/0 0 0/0037
I+ R 6 .
G5 X $#L ' $
1L # $ + I # miR-378
M ?!$ / # ! rs1076064
=5 , + ! " + @ + !
Case group (n=100)
Control group (n= 100) mir378
(rs1076064) % % Pvaluea OR 95 % CI
TT 80/10 96/0 0/3156 0/863 0/1-314/362
TC 10/60 4/0 0/0423 1/0339 0/1-062/6392
CC 9/30 0 0/0019 4/031 0/5-843/075
, -.( ( * /0 1(
2 D miR-378
) 34 5 ) 3$
/
12097
G
1 . 3.$g #$ #
" PCR / " :$
rs1544410 .
Q% ! 1 5 7 :$"
I$g "
466PCR k ! . / G " %R 8
(! , " :$"
50 + 100
" %R
G 2 . = #] " C " m ] , " 3.$g V )#
k ! .BSMI 1
PQR 3$ + ) $ 5
, 3.$g " )?
466 266 + 204 k ! . " %R 2
, 3.$g " I # 3$ $ $ 5 266
+ 204 k ! + " %R 3
$ 5
PQR 3$ $
, I$g " )?
466
" %R (! , .
100 , nA2 M ` o + ! .
+ c "
* )#
@
u ( 39 ^D 2 K y 6 . 7# = ( (P . 7# ) : ( E * ;-. ) #
) 21
$ E 6 & A B L .(
240 . 400
2 K y 6 . 7# )( 3 * * - C &
. :5 *
*
^F*
U 5 2 * ) ( ! D 1! ) #
) :5 * 22 ( A B L . ::E ( *
, -.( ) 2 2 *
d A 98 . y 6 . 7# D ) ( * )
O I 1 * )( [ 73E ) # 3
6 C & * 1 / 0 ( 39 ^D ) ( #
M * . (
$ ( 9 ( I 1 * )( )
. ( ^D 6 . 7# * 6 0$
z . K
E ( I 1 * )( [ 73E E & ! Y 5 E ::E HLA-DQ
HLA-DR HLA-
& . :5 * DP ) #
HLA-DPA1 HLA-DPB1
: . 2 2 e ( y 6 . 7# = 6 C * ;-.
- q E - ( & * 6 5 HLA-
DPA1 HLA-DPB1
0 -E ( 9
O :E ) *
/9 y 6 . 7# = I( B L 2 :e . 5 *
L* ( ( * Y ! 2 * )
= ! { F ) #
) * y 6 . 7#
23 E 6 5 1 | O W ) * .(
<1 4 b DQw1 ) ( 2 K y 6 . 7#
24 .(
2 K y 6 . 7# * ( 3 * x . #
) #
DQB1*0303 DRB1*08
6 5 &
) :# f & 1 C ! & ( * 3E E 25
.(
& { F A B L 2 3 2 2 E
^D 6 y 6 . 7# = * ! & ( 3 * ( ( #
. ( F3# B L * E 5 * 5 M 34
2 mL & ( 3#
D miR-378 ( (
173 E B L 2 K 6 . 7# * - ( 3 *
2 mL E : 1 (
D miR-
6 . 7# . * = B , -.(378 n * E ( B
) ( F3#
26 : .(
$ ) ( * & ( 3#
400
= * ! (P . 7# : ( E * - ( 3 * A t. 6 3# y 6 . 7#
1(
2
Y ( }$ E : 1 ( E B L ( D :e ( T
rs2228570 5 .P * ( 3 D 0 b . .
* 6 C O - * ) -E : ( E * * [ 5 & * 2 YI $ n * E 5 * 5 y 6 . 7# =
( F3# B L )
27 ( c D4. ( ^ ( 3# & .
6 ( & : 64.
& ) # : E E ) #
* B * &! # 3#
3$( YM 6 C *
y 6 . 7# = 706
( V B L ( ( 1 (
E 44 * B L 2 . * 6-W = * 1
2 * , -.( ( * ( <:
10 ( 6 ( 9
&
) SLC10A1 HLA-DP
HLA-C CXCR5
CXCL13 TLR3
TLR4 TLR9 UBE2L3
(
& & ( 3$( YM 6 C 9 !
@ HBV
98 . Y* V ^# E . 5 = 3$( YM O D
x . E ( & ( y 6 . 7#
rs355687 CT
: 5 ( x . E 0E * 0 D (
(CC : 5
. 5 # & B L 2
& ( 6 ( E #
CXCL13 * * B *
3$( YM 6 C
* 3# y 6 . 7# = )
28 ^ ( 3# r 8 .(
E E o( K CXCL13
z 1 61 * ( C
@: ( . D [ . E . E 6 C ( ( 4 b . CXCL13-CXCR5
6 C ( ) #
( V ( * ( E :. "
61 ) 29 .(
( B L M ) ~ # E : 1 & ( 3# r #
2 5 :e 2 * a -.(
f D ) #
) ( F3# B L * E ( 8 ( 30
.(
5 :e A B L = * O $ # * ) #
D 2 2 mL * )( | b & * * D
* 6 B1 ) ( | b 2 2
31 .(
:B A 1 M & n E " 3#
& ( )(
miR-378 1( $ (
rs1544410 8
Y ! 65 C
LM ) * ) E( * & : * .
( 3 * / 1 2 * . 5 1 < ( y 6 . 7#
:B j M
* )(
)
:e 7 . 1
rs1076064 5 &
miR-378 x . (
) #
:e [ 65 8 A " 3# A " # B -a rs1544410 5 2 &
( K0* ^D D
.( - * . ( y 6 . 7#
1 3 & * & .
7 . 6 B1 * ) b•. : 2 ( A/G
D 2
Y ! 9:. ( LM ) * ) E( * & : * C
y 6 . 7#
E & 3# . 5 1 < ( .
Y ) * h . 2 & n 1 ( O ) #
* * * ( 3 * 1
/ 80
% * * / 1 ( 5 * 96
%
, -.( ( * /0 1(
2 D miR-378
) 34 5 ) 3$
/
12297
)( ! ( 1 M 2 E * &
P>0.05) Y ( ( .(
A 1 M 6 . ) #
:B 7 . h . ( ( )(
CC & ( CT
5 :e ( t. [ rs1076064
1 (
. 5 * 5 ^D y 6 . 7# = ( .
# ! J+ 2
1 * _ $ D :5( E ( &
E * 5(
22030503951006 "
= 7 k. 2 * . 5 * # $ ! )( ! 21 ^# d 6 B : * ( V
"
# $ !
KE & :E( E &P q0
K -. 3 2 * & ( 3 * A D D4.
) 1 E
./ 3 3 )( 3# ^# d 2 @ (
References
1. He LJ, Zhang HP, Li HJ, Wang J, Chang DD. Effect of Serum Vitamin D Levels on Cellular Immunity and Antiviral Effects in Chronic Hepatitis B Patients. Clinical laboratory. 2016;62(10):1933-1939.
2. Shi YX, Huang CJ, Yang ZG. Impact of hepatitis B virus infection on hepatic metabolic signaling pathway World J Gastroenterol. 2016;22(36):8161.
3. Hoan NX, Khuyen N, Binh MT, Giang DP, Van Tong H, Hoan PQ, et al. Kremsner PG, Velavan TP. Association of vitamin D deficiency with hepatitis B virus-related liver diseases. BMC Infect Dis.
2016;16(1):507.
4. Tavakolpour S, Sali S, Gachkar L.
Association of plasma levels of vitamin D with chronic hepatitis B infection. Hepatitis monthly. 2016;16(1):1.
5. Xu L, Gao H, Huang J, Wang H, Zhou Z, Zhang Y, et al. Antiviral therapy in the improvement of survival of patients with hepatitis B virus‐related hepatocellular carcinoma treated with sorafenib. J Gastroenterol Hepatol. 2015;30(6):1032- 1039.
6. Dede Sit BE, Atay AE, Kayabaşı H. Is hemodialysis a reason for unresponsiveness to hepatitis B vaccine? Hepatitis B virus and dialysis therapy. World J Hepatol. 2015 18;7(5):761.
7. Gao XR, Wang CM, Wang WJ, Han GR, and Zhang, JQ Serum 25-hydroxyvitamin D status in pregnant women with chronic hepatitis B virus infection. J. Infect. Dev.
Ctries., 2015. 10(8), 851-586.
8. Schiller A, Timar R, Siriopol D, Timar B, Bob F, Schiller O, et al. Hepatitis B and C virus infection in the hemodialysis population from three romanian regions.
Nephron. 2015;129(3):202-208.
9.
10.Li JH, Chen DM, Li Z, Liu Y, Gao JR, Zeng XJ, et al. Study on association between vitamin D receptor gene polymorphisms and the outcomes of HBV infection. Zhonghua yi xue yi chuan xue za zhi= Zhonghua yixue yichuanxue zazhi=
Chinese j of med gen. 2006;23(4):402-405.
11.He N, Wang F, Ma C, Li C, Zeng X, Deng Y, et al. Chemiluminescence analysis for HBV-DNA hybridization detection with magnetic nanoparticles based DNA extraction from positive whole blood samples. J Biomed Nanotechnol. 2013 1;9(2):267-273.
12.Jansen L, de Niet A, Stelma F, van Iperen EP, van Dort KA, Plat-Sinnige MJ, Takkenberg RB, Chin DJ, Zwinderman AK, Lopatin U, Kootstra NA. HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels J Hepatol 2014 1;61(4):730-737.
13.Kim HS, Park JW, Jang JS, Kim HJ, Shin WG, Kim KH, et al. Prognostic values of α- fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study .J Clin Gastroenterol Hepato. 2009;43(5):482-488.
14.Lim S, Han J, Kim GM, Han KH, and Choi HJ. Hepatitis B viral load predicts survival
, -.( ( * /0 1(
2 D miR-378 ) 3$ ) 34 5
/
12497
in hepatocellular carcinoma patients treated with sorafenib. J. Gastroenterol. Hepatol., 2015. 30(6),1024-1031.
15.Beard JA, Bearden A, Striker R.Vitamin D and the anti-viral state. J Clin Virol. 2011;
50: 194-200.
16.Bitetto D, Fabris C, Fornasiere E, Pipan C, Fumolo E, Cussigh A, et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C.
Transpl Int. 2011; 24: 43-50.
17.Zitt E, Sprenger-Mähr H, Knoll F, Neyer U, Lhotta K. Vitamin D deficiency is associated with poor response to active hepatitis B immunisation in patients with chronic kidney disease. Vaccine 2012; 30:
931-935.
18.Mohamadkhani A. Long Noncoding RNAs in Interaction With RNA Binding Proteins in Hepatocellular Carcinoma. Hepat Mon.
2014;14(5):e18794.
19.Zhang X, Hou J, Lu M. Regulation of hepatitis B virus replication by epigenetic mechanisms and microRNAs. Front Genet.
2013;4:202
20.Pedersen AW, Holmstrom K, Jensen SS, Fuchs D, Rasmussen S, Kvistborg P, et al.
Phenotypic and functional markers for 1alpha,25-dihydroxyvitamin D(3)-modified regulatory dendritic cells. Clin Exp Immunol. 2009;157(1):48–59.
21.Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215
22.Fiorino S, Bacchi-Reggiani L, Sabbatani S, Grizzi F, Di Tommaso L, Masetti M, et al.
Possible role of tocopherols in the modulation of host microRNA with potential antiviral activity in patients with hepatitis B virus-related persistent infection:
a systematic review. Br J Nutr.
2014;112(11):1751-1768.
23.Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, et al.
Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006;355(8):763- 778.
24.Burns GS, Thompson AJ. Viral hepatitis B:
clinical and epidemiological characteristics..
Cold Spring Harb Perspect Med.
2014:a024935.
25.Thio CL, Astemborski J, Bashirova A, Mosbruger T, Greer S, Witt MD, et al.
Genetic protection against hepatitis B virus conferred by CCR5Δ32: evidence that CCR5 contributes to viral persistence. J Virol. 2007;81(2):441-445.
26.vinh quốc Lương K, Nguyễn LT.
Theoretical basis of a beneficial role for vitamin D in viral hepatitis. World J Gastroenterol.: WJG. 2012;18(38):5338.
27.Mohamadkhani A, Bastani F, Khorrami S, Ghanbari R, Eghtesad S, Sharafkhah M,et al. Negative association of plasma levels of vitamin D and miR-378 with viral load in patients with chronic hepatitis B infection.
Hepat Mon. 2015;15(6).
28.Peng Q, Yang S, Lao X, Li R, Chen Z, Wang J, et al. Association of single nucleotide polymorphisms in VDR and DBP genes with HBV-related
hepatocellular carcinoma risk in a Chinese population. Plos one. 2014;9(12):e116026.
29.Wan Z, Lin X, Li T, Zhou A, Yang M, Hu D, et al. Genetic variant in CXCL13 gene is associated with susceptibility to intrauterine infection of hepatitis B virus. Scientific reports. 2016;6:26465.
30.Ji X, Zhang Q, Li B, Du Y, Yin J, Liu W, et al. Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence, liver cirrhosis, and hepatocellular carcinoma.
Infect Genet Evol. 2014;28:201-209.
31.Hung CH, Hu TH, Lu SN, Chen CH, Wang JH, Lee CM. Association of vitamin D receptor gene polymorphisms with response
to peginterferon plus ribavirin in Asian patients with chronic hepatitis C. J Formos Med Assoc. 2016;115(4):278-83.
32.Uitterlinden AG, Fang Y, van Meurs JB, Pols HA, van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004;338(2):143- 156.
, -.( ( * /0 1(
2 D miR-378 ) 3$ ) 34 5
/
12697
A study of Polymorphism of Vitamin D Receptor and miR-378 on Vaccination non-responding in Pregnant Women suffering from Chronic
Hepatitis B Infection
Shahmohamadi P1, Ahmadizadeh C*2
1.Department of molecular genetics, Faculty of Basic Science, Islamic Azad University, Ahar Branch, Ahar, Iran 2.Assistant Professor, Department of Microbiology, Faculty of Basic Science, Islamic Azad University, Ahar Branch, Ahar, Iran
Received: 17 Oct 2018 Accepted: 3 Dec 2018
Abstract
Background: Hepatitis B is a common infectious disease leading to hepatic cirrhosis and hepatocellular carcinoma. Studies have shown that serum levels of vitamin D and mir378 have a reverse relationship with the hepatitis B. The present study was conducted to determine the relationship between vitamin D and miR-378 receptor polymorphism on vaccination non- response in pregnant women suffering from chronic hepatitis B.
Materials and Methods: This study examined 150 subjects including subjects with vaccination history and without hepatitis B, and subjects with vaccination history and with hepatitis. Genomic DNA was extracted using a salt saturation method. Then, RFLP- PCR method and SSCP- PCR techniques were used for miR378 to determine the mutations of Vitamin D. The mutant frequency and its rate were determined using SPSS software. The mutant alleles' rate was determined by analysis of variance.
Results: Results showed that there were no significant differences in mutant alleles between case and control groups in rs1544410 region (P=0.119) and allele C can be considered as a biomarker for hepatitis B. There was significant difference between case and control groups regarding rs1076064 allele and genotypic frequency (P=0.0037).
Conclusion: It can be stated that rs1544410 polymorphism (P=0.0037) could not have a significant role in hepatitis B. In other words, A/G frequency had a significant role in hepatitis B and only allele C could be considered as a biomarker for hepatitis B risk.
Keywords:polymorphism, hepatitis B, vitamin D, miR-378
*Citation: Shahmohamadi P, Ahmadizadeh C. A study of Polymorphism of Vitamin D Receptor and miR-378 on Vaccination non-responding in Pregnant Women suffering from Chronic Hepatitis B Infection. Yafte.
2019;20(4):116126.